Pfizer.
The US pharmaceutical giant Pfizer, who made an unsuccessful attempt to buy Astra Zeneca last year, is reported to have a number of other companies on buying radar.
Pfizer announced recent acquisition of a US development company, Hospira. The price tag was $ 17 billion, or about $ 90 per share, representing a premium of nearly 40 percent.
In comparison with the 120 billion dollars that Pfizer was willing to pay for Astra Zeneca is Hospira affair peanuts. Therefore, many experts believe that the US pharmaceutical giant’re looking for more companies to buy.
– You do not go from a potentially large acquisition of 120 billion dollars into something more like an Hors d’oeuvre said John Boris on The research firm SunTrust Humphrey.
According to him, Pzifer be looking to purchase a large pharmaceutical company and mention Glaxosmithkline, AbbVie and Bristol-Myers Squibb as potential acquisitions.
Kevin Kedra, an analyst at Gabelli & amp; Co., believe that Pfizer is looking for Actavis, which just announced an acquisition of Botox maker Allergan.
Another company mentioned in speculation is Mylan Pfizer already cooperating with areas such as drug Epipen, writes Bloomberg.
No comments:
Post a Comment